Good Evening Market Enthusiast,
Tomorrow at 8AM EST, we’re dropping a fresh breakdown on a tiny Nasdaq-listed healthcare AI name that may be sitting in one of the more interesting disconnects on our radar right now.
This one was recently sitting around $3.53. Analysts have a $7
target on it. That is nearly 100% higher than today’s close, and that is before you factor in the fresh catalyst stack that has been building since our last coverage.
Since then, the company has announced three new PRs: a major medical institution agreement, new AI recognition, and a newly issued U.S. patent tied to machine learning-based pain evaluation. Not exactly sleepy stuff.
The bigger picture is what makes this more interesting. The company is targeting chronic low back pain, a massive healthcare problem where physicians still need better tools to identify which spinal discs are actually causing pain.
And here is the balance-sheet kicker: the company has reported $21.6 million in cash, zero debt, and runway into 2028.
Tiny name. Big medical category. Fresh validation. Patent protection. Analyst target sitting nearly 100% above today’s close.
Tomorrow morning, we’re breaking down why this healthcare AI story may be getting much harder to ignore.
Full release drops tomorrow at 8AM EST.
Max Masters
Co-founder, Market Tips
Newsletter
